Meta-analysis 24 studies (3015 hidradenitis suppurativa pts) taking IL-17 inhibitor, IBD adverse events were rare, w/ no difference in IBD risk betw IL-17i & PBO (0.23% vs 0 of 2572 vs 1066 pts respectively) thru wk 16. The reported assocn of IL-17 inhibitors w/ IBD risk is https://t.co/kDwR5Fc1zI

Difficult PsA is called ‘difficult-to-manage’ (D2M) or ‘treatment-refractory’ dz (TRD). Data from 5 Nordic PsA registries 14,362 ps, D/Cs of ≥2/≥3/≥4 b/tsDMARDs in 36%/18%/10%. Freq of D2M low 2%/3%/3%, & TRD was 1.2%/1.2%/0.8%. Female #s, depression, & opioids incr w/ # of https://t.co/FkQU5BVRn2

RCT 451 chronic LBP in general practice shows 8-wk telehealth mindfulness reduced pain intensity and interference at 6 months compared with usual care, BUT changes did not meet the prespecified mean 1-point MCID between groups. Is it worth doing? https://t.co/H4oYTeq1is https://t.co/cozq7gGnYO

Obesity isn’t just a comorbidity—it can influence inflammation, disease activity and treatment response. Join our second Tuesday Night Rheumatology webinar this month as leading experts explore the biology of fat and its impact on rheumatic disease. Register: https://t.co/jsWungkcG6

Osteoarthritis, Obesity and GLP-1s https://t.co/SGnWksQBpT https://t.co/TPxM4aj7bd

QD Clinic: Obesity: Escalate or Reassess? Dr. Mrinalini Dey, London, presents this QD Clinic as part of RheumNow's "The Obesity Imperative" presented in September 2026. https://t.co/wt5N6RZmg6 https://t.co/3EyRa1WC9U

ACP Position Statements on the Ethics of AI in Medical Practice Recently JAMA updated its guidance on artificial intelligence (AI) in medical publications. Now, the ACP has published a position paper regarding the use and ethical considerations for the use of AI in medical https://t.co/J6qgfI2Sgt

Treating Obesity is Disease-Modifying (9.4.2026) Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow. New drugs approved, new drugs halted and some drugs out of control. https://t.co/ojBOosSWMX https://t.co/K4DvUK24Pb

High BMI decreases the odds for MDA in PsA, esp w/ TNFi Rx (but not Inflx, IL-17i, IL-12/23i, IL-23i, JAKi). Longitudinal PsA cohort 1291 pts (mean BMI 29); Higher BMI independently assoc w/ signif. lower odds for MDA (OR 0.97), also female, age, smoking, FM & Xray damage. https://t.co/zAJ8Pmk1HY

Denzel Washingtons plan for self improvement - great advice to anyone starting out, looking for direction. https://t.co/0HcLyDAfNP https://t.co/DaqObRNgLW

Epic Cosmos study of GLP-1RA Rxs in 3.5 million children (8–11 yrs) - very few 0.6% recv a GLP-1RA (20,282 kids) - Rx went from 0.03% (2019) to 9.3% (2026-310-fold incr). More likely in older, girls, obese kids. Most GLP-1 kids had severe obesity (93.7 percent) https://t.co/JW6SXxJjA0

Cohort analysis shows autoimmune rheum Dz (AIRD) pts who recv COVID vax w/ boosters & updates were 41%, 71%, and 69% less likely to have COVID-related hospitalization (vs no Vax). If only initial vaccine series (without booster/updated vaccine), risk reduction was 5.6%. (n= https://t.co/NdEKKWdOAy

Leeds study of 44 patients idiopathic inflamm myopathy (IIM) pts Rx w/ rituximab showed a 70% response 4-6 mos post RTX. Responders had higher TIS (50·0 vs 17·5). Using highly sensitive flow cytometry, @ 2 wks responders had lower #s memory B cells & Plasmablasts. Is there a role https://t.co/HTxOIxkezs